Intra-Cellular Therapies Inc. (ITCI) - Long-Term Liabilities to Capital

This chart of the market valuation for Intra-Cellular Therapies (ITCI) on the GURU.Markets platform, showing a value of 0.01, is based on a steady cash flow from the sale of its drug for the treatment of bipolar disorder and schizophrenia. However, high revenue concentration in a single product creates vulnerability to insurance limits. The company's future growth relies on expanding the list of approved indications and increasing therapy accessibility for new patient groups.

This indicator measures the share of long-term loans in net assets, determining the degree of financial leverage and the pressure on profitability. For Intra-Cellular Therapies (ITCI), this balance is critical when scaling sales of the drug CAPLYTA. By analyzing the current level of long-term financial dependence, an investor assesses the capital's resilience in servicing borrowed funds. Low values minimize bankruptcy risks, confirming the fundamental stability of the biopharmaceutical business.